208 related articles for article (PubMed ID: 27049255)
1. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
2. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
5. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
7. Advances in the treatment of hepatitis C.
Lawrence SP
Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
[TBL] [Abstract][Full Text] [Related]
8. Why do I treat my patients with mild hepatitis C?
Calvaruso V; Craxì A
Liver Int; 2016 Jan; 36 Suppl 1():7-12. PubMed ID: 26725891
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
12. Emerging treatments for hepatitis C.
Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis.
Mantravadi S
Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676
[No Abstract] [Full Text] [Related]
14. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
15. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
17. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
18. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
Gray E; O'Leary A; Kieran JA; Fogarty E; Dowling T; Norris S;
J Viral Hepat; 2016 Sep; 23(9):677-86. PubMed ID: 26996144
[TBL] [Abstract][Full Text] [Related]
19. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
20. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]